The outlook for obesity from 2026 to 2030: From consolidation to acceleration

Luke Greenwalt

Vice President, Thought Leadership & Innovation, IQVIA U.S.

2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent. From 2026 onwards we will see:

The first oral obesity medicines, but also the first off-patent competition
Lower prices and greater accessibility than ever before, but also rising concerns about how people successfully maintain their weight loss and realise the benefits of impacts on comorbidities of obesity
Greater competition, innovative and off patent, from a wider group of players, but increasing need to differentiate in an increasingly complex, segmented market.
New areas of focus beyond weight loss into new labels reflecting comorbidity benefit, maintenance, and muscle preservation

By joining our speakers, you will learn:

What we can expect in terms of key events and features of the 2026 obesity treatment availability, obesity medicines and beyond
The drivers of global obesity market from 2026 to 2030
Key issues to be aware of and to plan for success in obesity to 2030

Secure your place now

Related solutions